In the United States, biosimilar launches have been met with disappointment over what many view as too-shallow discounts to reference products’ list prices. However, as Aurelio Arias, a consultant at IQVIA, explained during the SMi 9th annual conference on Biosimilars and Biobetters, held September 26-27 in London, United Kingdom, the substantial savings that the European market has realized with biosimilars are not necessarily reflected in list prices, either.
In the United States, biosimilar launches have been met with disappointment over what many view as too-shallow discounts to reference products’ list prices.
However, as Aurelio Arias, a consultant at IQVIA, explained during the SMi 9th annual conference on Biosimilars and Biobetters, held September 26-27 in London, United Kingdom, the substantial savings that the European market has realized with biosimilars are not necessarily reflected in list prices, either. Arias noted that in Europe, discounts on list prices at the time of launch are not that much greater than they are in the United States, as most European biosimilars appear to launch at a 10% to 20% discount to the originator. These are “not necessarily the huge savings we were promised initially,” he said.
However, net pricing is likely to tell a different story. While Arias explained that net pricing is similar to “the dark arts” and can be difficult to assess, the available data in Europe show that health systems are achieving discounts of as much as 70% for some drugs, primarily for molecules that have 3 biosimilar products available.
He noted that the number of entrants above 3 did not make a substantial impact on price, however, and that in nations where only a single manufacturer can win a tender, average net costs are higher than they are in countries that have multiple-winner tenders.
The discounts that health systems have been able to achieve have proven to be deep enough to drive substantial uptake (Arias cited approximately 70% uptake for biosimilar trastuzumab in the Netherlands 2 months after the first product launched), even when adopting a biosimilar means forgoing newer devices or routes of administration.
According to Arias, in some health systems that had previously moved patients with HER2-positive cancer to subcutaneous administration of the reference trastuzumab (Herceptin), clinicians reverted to intravenous administration of the reference product as a way to prepare patients for the switch to the intravenous biosimilar.
Overcoming the challenge of moving patients to a biosimilar version of adalimumab may be even less of a challenge; while Humira maker AbbVie has created a reformulated version of the reference drug—administered with a slightly smaller needle that is designed to cause less pain at the injection site—Arias says that physicians and health systems are likely to trade a minor difference in patient discomfort for substantial cost savings. In fact, he noted, some health systems are reporting that they plan to run their stocks of Humira dry so that they can replenish their pharmacies with a biosimilar product on the first day of their tender agreements.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.
Rising Biosimilar Adoption for an Italian Payer Will Benefit National Health Care System, Patients
April 9th 2024Data from 2021 and 2022 indicates increasing biosimilar use in an Italian health care company, with potential for full adoption in the future, benefiting both the National Health System and citizens through efficient and sustainable health care policies.